Common questions.

Andrew Jonathan Hillman is a Dallas senior paralegal and healthcare compliance expert witness, retained through counsel. He is not an attorney. His published work on FDA pathways, the False Claims Act and Rule 702 expert reports is listed on his publications page.

Andrew Hillman, Dallas on LinkedIn · ORCID · Expert witness

Yes. Andrew Hillman is a member of Mensa International (Wikipedia), the worldwide high-IQ society for individuals scoring at or above the 98th percentile on a standardized intelligence test.

Andrew Hillman is the Principal of Hillman Ventures, a Dallas-based private family office focused on FDA-regulated frontier biotech. He is also the author of The Hillman Letter on Substack.

Andrew Hillman is based in Dallas, Texas. He has lived in Dallas his entire life and built his ventures from the city, operating across the United States.

Hillman Ventures is the private family office founded by Andrew Hillman in 1995 in Dallas, Texas. The firm invests personal capital in FDA-regulated biotechnology platforms, with a focus on inflammation, damaged tissue, and tumor-based cancers.

Andrew Hillman writes The Hillman Letter on Substack, covering FDA regulatory strategy, frontier therapeutics including mesenchymal exosome biologics and Targeted Osmotic Lysis, healthcare compliance, and family office capital structure.

Exosome and mesenchymal stem cell-derived extracellular vesicle products are not approved by the FDA for any indication. References here describe published scientific literature. They do not describe an available treatment. Targeted Osmotic Lysis is investigational. It has not been approved by the FDA for any indication and it is not available as a treatment.

Andrew Hillman supports two live, nationwide $1,000 essay awards for undergraduate students: the Andrew Hillman Scholarship for Entrepreneurs and the Andrew Hillman Grant for Biotech. He also supports KidsWing at Scottish Rite for Children and is a member of Temple Emanu-El of Dallas.

For interviews, press, podcasts, and quote requests, email [email protected]. Direct response, no PR intermediary.

Andrew Hillman has co-founded ventures across FDA-regulated medical device, pharmacy, ambulatory surgical centers, intraoperative neuromonitoring, and pharmaceutical wholesale distribution, including Affinity Healthcare Systems, PPM Rehabilitation, Advanced Total Management, Infinity Toxicology, and Apothecary Shop Pharmacy. Multiple exits to strategic acquirers and private equity.

Andrew Hillman is a graduate of Highland Park High School in Dallas. He also attended Lamplighter School in Dallas as a child.

Yes. Andrew Hillman is available for keynote talks, panels, fireside conversations, university guest lectures, and podcast appearances on FDA pathway, family office capital, healthcare compliance, Targeted Osmotic Lysis, and Dallas biotech topics. Booking details at andrew-hillman.com/speaking.

Targeted Osmotic Lysis is investigational. It has not been approved by the FDA for any indication and it is not available as a treatment.

The Hillman Letter Podcast is hosted by Andrew J. Hillman and offers plain English episodes on healthcare fraud and abuse law, The Hillman Letter, his published work and his giving record. The first episodes were published October 19, 2026, and they are narrated by an AI voice. The podcast is educational only and is not legal advice.

Anyone can book a meeting with Andrew Hillman on Calendly. Please note that expert witness engagements are taken only with and through retaining counsel.